RealRate

PHARMACEUTICAL 2012

Alnylam Pharmaceuticals INC
Rank 112 of 196



PHARMACEUTICAL 2012

Alnylam Pharmaceuticals INC
Rank 112 of 196

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 81% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 12% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	152,028
Cost of Goods Sold	0
Intangible Assets	275
Liabilities, Current	80,990
Liabilities, Non-Current	716
Other Assets	114,971
Other Compr. Net Income	-879
Other Expenses	0
Other Liabilities	82,214
Other Net Income	79,926
Other Revenues	0
Property and Equipment	14,643
Research and Development	99,295
Selling, General and Administrative Expense	38,280

Output Variable	Value in 1000 USD
Assets	281,917
Liabilities	163,920
Expenses	137,575
Revenues	0
Stockholders Equity	117,997
Net Income	-57,649
Comprehensive Net Income	-58,088
BaseVar	332,108
ECR before LimitedLiability	89%
Economic Capital Ratio	222%